NCT07173595

A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 186 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, multicenter, dose-escalation, dose-expansion and efficacy-expansion phase I clinical study to evaluate the tolerability, safety, pharmacokinetics and preliminary antitumor activity of QLS2309 injection in patients with CD70+ relapsed/refractory hematologic malignancies.

Conditions

• Relapsed or Refractory Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	QLS2309	initial dose - MTD; QW; intravenous infusion

Timeline

• Start date: 2025-12-05
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-09-15
• Last updated: 2026-01-02

Locations

1 site across 1 country: China